MedPath

Neostigmine

These highlights do not include all the information needed to use NEOSTIGMINE METHYLSULFATE safely and effectively. See full prescribing information for NEOSTIGMINE METHYLSULFATE. NEOSTIGMINE METHYLSULFATE injection, for intravenous use Initial U.S. Approval: 1939

Approved
Approval ID

95fb1b3d-be9a-fdb4-e053-2a95a90a5e90

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

May 15, 2023

Manufacturers
FDA

Medical Purchasing Solutions, LLC

DUNS: 601458529

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Neostigmine

PRODUCT DETAILS

NDC Product Code71872-7178
Application NumberANDA209135
Marketing CategoryC73584
Route of AdministrationINTRAVENOUS
Effective DateMay 15, 2023
Generic NameNeostigmine

INGREDIENTS (6)

PHENOLInactive
Quantity: 4.5 mg in 1 mL
Code: 339NCG44TV
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
SODIUM ACETATEInactive
Quantity: 0.2 mg in 1 mL
Code: 4550K0SC9B
Classification: IACT
ACETIC ACIDInactive
Code: Q40Q9N063P
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT
NEOSTIGMINE METHYLSULFATEActive
Quantity: 1 mg in 1 mL
Code: 98IMH7M386
Classification: ACTIB
© Copyright 2025. All Rights Reserved by MedPath
Neostigmine - FDA Approval | MedPath